FDA Holds Public Hearing on Psychedelic Therapies

September 15, 2026

Photo by Quang Vuong via Pexels.

The FDA doesn't usually draw a crowd of veterans, therapists, drug policy lobbyists and pharmaceutical executives into the same room, but that's what happened on September 14, 2026, when the agency convened a hybrid public hearing at its White Oak campus in Silver Spring, Maryland. The topic was psychedelic therapeutics, specifically how the agency should think about developing and evaluating drugs like psilocybin, MDMA analogs and LSD derivatives for conditions such as depression and PTSD.

This wasn't a hearing about rescheduling psilocybin under the Controlled Substances Act, and it wasn't a referendum on state-level legalization efforts. The docket, FDA-2026-N-7542, traces back to an executive order President Trump signed in April 2026 directing federal agencies to accelerate treatments for serious mental illness. Written comments on the docket remain open through October 5, 2026, giving researchers, clinicians and companies more time to shape the record. What emerged over four hours of testimony was a fairly candid airing of a real tension: regulators, drugmakers and advocates all want faster access to therapies that seem to be helping people in trials, but nobody wants to repeat the mistakes of drug approval processes that moved ahead of the evidence.

What the Hearing Was -- and Wasn't -- About

Photo by Héctor Berganza via Pexels.

The mechanics of the hearing matter as much as its substance. FDA held the session from 12:30 to 4:30 p.m. ET in Building 31, Room 1503, with an option for remote attendees to log in and submit oral comments virtually. That hybrid format let out-of-state clinicians, patient advocates and smaller biotech firms participate without the cost of traveling to Maryland, which likely broadened who showed up to speak.

Procedurally, this was a Part 15 hearing, a formal mechanism FDA uses to gather public input outside of a rulemaking or an individual drug review. The agency was blunt about the boundaries: this wasn't the venue for discussing specific pending drug applications, decisions about how psychedelics are scheduled under federal drug law, or the broader push toward legalizing psychedelic substances for general use. Anyone hoping to relitigate scheduling policy or lobby for a particular company's application was pointed elsewhere.

Instead, the focus stayed on how psychedelic drug products might be developed and used specifically in supervised, clinically supportive settings, meaning therapy delivered alongside trained clinicians rather than at-home or unsupervised use. Deputy Center Director Marta Sokolowska opened the proceedings by framing the hearing as one piece of a larger, whole-of-government effort to understand both the therapeutic opportunities psychedelics present and the public health considerations that come with them. That framing set the tone for what followed: a hearing more interested in process and evidentiary standards than in headlines.

New CDER Director Lays Out a Framework

Photo by RDNE Stock project via Pexels.

The most closely watched attendee wasn't a company executive but the FDA's own newly appointed Director of the Center for Drug Evaluation and Research, Michael Davis, who stepped into the role after previously serving as the agency's Chief Medical Officer. Just days before the hearing, Davis published a paper in the New England Journal of Medicine laying out a proposed framework for how psychedelic drugs should move through development and approval. In it, he argued the agency is meeting a real moment of need on conditions like major depressive disorder and PTSD, conditions where existing treatments often fail a meaningful share of patients.

Davis's framework didn't arrive in isolation. Around the same time, FDA finalized its guidance document titled Psychedelic Drugs: Considerations for Clinical Investigations, closing out a process that began with draft guidance released back in 2023. The final guidance is notable less for what it changes than for what it reaffirms: psychedelic drug development programs are expected to meet the same regulatory standards and clear the same evidentiary bar as any other class of drug. There's no shortcut built in for psilocybin or MDMA-based therapies simply because of cultural momentum or political interest.

That's a meaningful signal to companies designing trials right now. It means blinding challenges (a persistent problem in psychedelic research, since patients and researchers can often tell who received an active dose), long-term follow-up requirements and standard statistical rigor aren't going away. Davis's public positioning, paired with the finalized guidance, suggests FDA leadership wants to be seen as encouraging without lowering the bar, a distinction several hearing participants pushed the agency to hold onto.

The Executive Order and Three Priority Vouchers

Photo by Mina Rad via Unsplash.

None of this hearing happens without Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness, which Trump signed on April 18, 2026. The signing ceremony itself became part of the story, since podcaster Joe Rogan was present for the event, a detail that critics later seized on as evidence that policy momentum around psychedelics was being driven by cultural cachet rather than clinical consensus.

Whatever the optics, the order had concrete follow-through. Shortly after it was signed, FDA issued three Commissioner's National Priority Review vouchers, a tool meant to speed up review timelines for drugs addressing urgent public health needs. The recipients were Compass Pathways, Transcend Therapeutics and the Usona Institute. Compass Pathways' voucher applies to psilocybin for treatment-resistant depression, while Usona's covers psilocybin for major depressive disorder more broadly. Transcend Therapeutics' voucher applies to methylone, an MDMA-related compound, for PTSD.

FDA has since published a webpage detailing its broader support for psychedelic drug development, including a collaboration with the Department of Veterans Affairs, an agency with obvious interest given the prevalence of PTSD and treatment-resistant depression among veterans. Whether these three priority vouchers actually shorten the road to approval, or just create the appearance of momentum, is something only time and completed trials will answer. Priority review vouchers speed up FDA's review clock once an application is filed; they don't change what evidence a company has to generate beforehand.

Caution From Drug Policy Advocates and Medical Groups

Photo by Product School via Unsplash.

Not everyone at the hearing was there to cheer the pace of change. Kevin Sabet, head of the Foundation for Drug Policy Solutions and a longtime voice of caution on drug policy, told FDA that psychedelics should earn approval the same way any other drug does: through rigorous science and controlled trials, not through political momentum or celebrity endorsement. Sabet said his core concern is that the industry could rush toward mass commercialization before the underlying research has caught up to the enthusiasm surrounding it.

Industry didn't universally push back on that caution. Robert Barrow, CEO of Definium Therapeutics, a company developing an LSD-based therapy, called the hearing a genuinely useful public dialogue and argued that psychedelics should simply be folded into normal drug development processes rather than treated as either a miracle category or a special threat. That's a notably measured position from someone whose company stands to benefit from faster pathways.

The American Psychiatric Association struck a similar balance in its comments, praising FDA's coordination with other federal partners like the VA while insisting that FDA's own independent safety and effectiveness determinations have to remain the foundation for any clinical use, not political directives or interagency enthusiasm. Doctors, pharmacists, therapists and veterans who testified largely echoed that theme, with many urging the agency to build clear guardrails around who can access these therapies and under what kind of supervision, rather than leaving those questions to be sorted out after approval.

Nothing about this hearing changes federal law today. No new rule came out of it, and FDA was careful to keep the discussion within the bounds of a Part 15 public comment process rather than a decision-making venue. What it does signal is an agency trying to carve out a workable regulatory lane for psychedelic therapeutics, one that responds to genuine unmet need in conditions like treatment-resistant depression and PTSD without abandoning the trial-based evidence standard FDA applies to every other drug class it reviews.

The real test comes over the next few years, as the three priority review vouchers issued to Compass Pathways, Transcend Therapeutics and Usona Institute either translate into approved therapies or run into the same trial design and blinding problems that have dogged psychedelic research for years. If those programs succeed on the strength of their data, the framework Davis outlined will look prescient. If they stumble, the hearing will be remembered as the moment FDA tried to thread a needle between political urgency and scientific patience.

In the meantime, psychedelic substances remain federally controlled, and state laws on their therapeutic or personal use vary considerably, from limited supervised-use programs in a handful of states to outright prohibition elsewhere. Patients hoping to access these treatments and businesses hoping to build around them should keep an eye on both tracks: what FDA does with its rulemaking and guidance documents, and what their own state currently allows, since the two aren't moving in lockstep and won't necessarily converge anytime soon.